menu

CME: Advances in the Management of Difficult-to-Treat Asthma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
x
Hello, there.
SUBMIT YOUR PATIENT CASE

CONSULT WITH SOME OF THE COUNTRY'S LEADING EXPERTS ON ASTHMA!

Submit your challenging patient case that could be featured in future educational programming.

Click HERE to engage with the experts!
CONTINUE TO PROGRAM

Advances in the Management of Difficult-to-Treat Asthma

Advances in the Management of Difficult-to-Treat Asthma
RestartResume
This multidisciplinary, virtual roundtable brings together clinicians and a patient to discuss clinical aspects of care in people with asthma.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

  • Overview

    The management of severe asthma has changed drastically after the introduction of biologics. However, their introduction comes with many questions, such as, When should they be used and in whom? This Care Team ForumSM brings pulmonologists and an allergist/immunologist in dialogue with a patient about the immunologic underpinning of asthma pathology and how it relates to identifying patients appropriate for step-up care with biologics.

  • Faculty Credentials

    Reynold Panettieri, MD
    Professor of Medicine, Robert Wood Johnson Medical School
    Vice Chancellor, Clinical & Translational Science
    Director, Rutgers Institute for Translational Medicine & Science
    Emeritus Professor of Medicine
    New Brunswick, NJ
     
    Michael E. Wechsler, MD, MMSc
    Co-Director, The Cohen Family Asthma Institute 
    Professor, Department of Medicine 
    Division of Pulmonary, Critical Care and Sleep Medicine 
    National Jewish Health 
    Denver, CO 
     
    Jonathan Corren, MD
    Clinical Associate Professor, Medicine and Pediatrics Division of Clinical Immunology and Allergy
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, CA 
     
  • Target Audience

    The target audience for this activity is US-based pulmonologists, allergists, and immunologists, as well as NPs and PAs who diagnosis and manage difficult-to-treat and severe asthma.

  • Learning Objectives

    Upon successful completion of this activity, participants should be better able to:

    • Distinguish between the different types of asthma based on underlying pathophysiology and biomarkers of disease in order to make personalized treatment decisions
    • Identify patients with poorly controlled or difficult-to-treat asthma who are eligible for step-up therapies, including new and emerging biologics
    • Incorporate new and emerging targeted biologics into the management of patients with severe or poorly controlled asthma when appropriate
  • Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

      

    This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with PIM.

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Disclosure of Conflicts of Interest

    The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    • Reynold Panettieri, MD
      AstraZeneca, Boehringer-Ingelheim, Equillium, MedImmune, RIFM, Theravance (Consulting Fees); AstraZeneca, Genentech, Sanofi/Regeneron (Speakers' Bureaus); AstraZeneca, Equillium, Medimmune, RIFM, Teva (Contracted Research)
    • Michael Wechsler, MD
      AstraZeneca, Boehringer-Ingelheim, Equillium Mylan, Gala Therapeutics, Genentech, Genzyme, GlaxoSmithKline, Novartis, Pulmatrix, Regeneron, Restorbio, Sanofi, Sentien Biotechnologies, Teva (Consulting Fees); AstraZeneca, Sanofi, Teva (Contracted Research)
    • Jonathan Corren, MD
      AstraZeneca, Genetech, Regeneron, Sanofi (Consulting Fees)

    DISCLOSURE DECLARATIONS
    The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

    DISCLOSURE OF UNLABELED USE
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • How to Receive Your Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.

    Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email inquiries@pimed.com.

  • Your Feedback is Important to Us

    COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
    INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

    *The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

    Rules and Regulations 
    This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

  • Media

    Internet

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Programs 12/16/19